Your home doesn't need an advanced degree to be smart. These devices will turn it into a high-tech haven through the miracle ...

Money blog: Major firms named and shamed for not paying minimum wage Today on the Money blog, Sky News' consumer hub - our regular Mortgage Guide reveals rates have risen for the first time in eight ...

We tested the best winter boots for women in cold, snowy, icy, and sloppy conditions. Our top picks include Sorel, Timberland ...

Lack of alternatives and unbeatable salaries are among many reasons why disadvantaged young Southeast Asians work gladly in ...

On paper, the opening of Finland’s online regime should be championed as a proven, high-value market being reborn for ...

The Global ABM Conference 2025 delegate brochure is packed with all the information you'll need ahead of booking your ticket. Our second ever Global B2B Marketing Agencies Benchmarking Report is back ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

Sky-high sales prospects for Bristol Myers Squibb's new schizophrenia treatment Cobenfy may have to be scaled down after a trial designed to expand the label of the recently approved drug failed.